Novartis, Pear in digital drug alliance

Novartis has announced a collaboration with Pear Therapeutics Inc to develop digital therapeutics for patients with schizophrenia and multiple sclerosis using mobile and desktop software. The new products would deliver clinically-proven treatments such as cognitive behavioural therapy.

Full text available to subscribers only. Click here for information on subscribing to MedNous.